Vadastuximab talirine
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD33 |
| Clinical data | |
| Other names | SGN-CD33A |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML).[1][2]
Development of vadastuximab talirine was discontinued in 2017 after a pivotal phase III clinical trial.[3]
- ^ Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Harrington KH, et al. (November 2012). "SGN-CD33A: A novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML". Blood. 120 (21): 3589. doi:10.1182/blood.V120.21.3589.3589.
- ^ "Pyrrolobenzodiazepine (PBD)". ADC Review / Journal of Antibody-drug Conjugates. 16 March 2015.
- ^ Hartley JA (July 2021). "Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy". Expert Opinion on Biological Therapy. 21 (7): 931–943. doi:10.1080/14712598.2020.1776255. PMID 32543981. S2CID 219725417.